Study to Evaluate the Safety and Efficacy of the Addition of Omarigliptin (MK-3102) Compared With the Addition of Sitagliptin in Participants With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin (MK-3102-026)
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 642 participants.
Also called NCT01841697
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 642 participants
- Sponsor
- Registry
-
NCT01841697 -
2013-000059-42
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- Not reported
- Registry status
- Completed
Technical summary
Registry record NCT01841697. Randomized; double masking; primary purpose treatment. Start 2013-06-13 (actual); primary completion 2014-11-17 (actual). Results posted on 2015-11-25.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Study to Evaluate the Safety and Efficacy of the Addition of Omarigliptin (MK-3102) Compared With the Addition of Sitagliptin in Participants With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin (MK-3102-026)
- Condition
- Type 2 Diabetes
- Intervention (Drug)
- Omarigliptin
- Intervention (Drug)
- Sitagliptin
- Intervention (Drug)
- Placebo to omarigliptin
- Intervention (Drug)
- Placebo to Sitagliptin
- Intervention (Drug)
- Open-label Metformin
- Intervention (Drug)
- Open-label Glimepiride
- Lead sponsor
- Merck Sharp & Dohme LLC
Record details
- Record id
cardio:ct-nct01841697- Content hash
30cdbbfc27b19c257aa783754f54b82c2388f253ca7d8d7da99da655cf2b405f